Immuno-Oncology News Articles

Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study
Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.
FDA Grants Nivolumab Priority Review for SCLC
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
Nivolumab OS Benefit Sustained in Long-Term Follow-Up for SCCHN
Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. 
FDA Approves Nivolumab/Ipilimumab for Frontline RCC
The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.
Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma
Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial. 
QoL Data Support Durvalumab Use in Locally Advanced NSCLC
Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.
 
Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC
The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC. 
Atezolizumab Shines in Long-term POPLAR Findings
Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.
Role of Immunotherapies Emerging in Gastric/GEJ Cancers
Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.
Role of Surgery Could Change Following Durvalumab Approval for Stage III NSCLC
Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.
Publication Bottom Border
Border Publication
x